Human Immunodeficiency Virus Viral Load Monitoring and Rate of Virologic Suppression Among Patients Receiving Antiretroviral Therapy in Democratic Republic of the Congo, 2013-2020.
[en] BACKGROUND: Antiretroviral therapy (ART) expansion and viral load as a treatment monitoring approach have increased the demand for viral load testing. Many hurdles affect the coverage, quality, and use of viral load results. Estimates of viral load monitoring and viral suppression rates are needed to assess the performance of ART programs and improve human immunodeficiency virus (HIV) management outcomes.
METHODS: People with HIV (PWH) viral load monitoring data were routinely collected in 84 health facilities in Kinshasa, Democratic Republic of the Congo (DRC), between 2013 and 2020. The number of PWH under ART, the number of participants with at least 1 viral load test result, the rate of viral suppression (defined as ≤1000 HIV ribonucleic acid copies per mL), and the mean turnaround time from sample collection to release of viral load test results were collected together with clinical data.
RESULTS: A total of 14 057 PWH were included in the analysis. People with HIV were mainly enrolled after the "test and treat" implementation. The patients were followed for a median period of 27 months. The proportion of PWH with at least 1 available viral load largely increased in recent years. The delay from sample collection to release of viral load test results decreased overtime, from 35 days in 2018 to 16 days in 2020. Pregnancy and advanced HIV disease were associated with a lower chance of viral suppression.
CONCLUSIONS: There has been considerable success in increasing viral load access for all PWH under therapy in DRC. Nevertheless, viral load testing should be intensified with a particular effort to be made in groups at higher risk of viral failure.
Disciplines :
Immunology & infectious disease
Author, co-author :
Mayasi Ngongo, Nadine; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Kamangu Ntambwe, Erick; Department of Molecular Biology of Basic Sciences, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
Situakibanza Nani-Tuma, Hippolyte; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Mbula Mambimbi, Marcel; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Mandina Ndona, Madone; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Longokolo Mashi, Murielle; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Bepouka Izizag, Ben; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Lukiana, Tuna; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Odio Ossam, Jérôme; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Mangala Sonzi, Donatien; Department of Internal Medicine, Infectious and Tropical Diseases, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo
Maes, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
Moutschen, Michel ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
El Moussaoui, Majdouline ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
Darcis, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
Human Immunodeficiency Virus Viral Load Monitoring and Rate of Virologic Suppression Among Patients Receiving Antiretroviral Therapy in Democratic Republic of the Congo, 2013-2020.
Petersen M, Balzer L, Kwarsiima D, et al. Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa. JAMA 2017; 317:2196-206.
Molina JM, Grund B, Gordin F, et al. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV 2018; 5:e172-80.
REPUBLIQUE DEMOCRATIQUE DU CONGO MINISTERE DE LA SANTE PROGRAMME NATIONAL DE LUTTE CONTRE LE SIDA ET LES IST "PNLS ". Guide de prise en charge int (c)gr (c)e du VIH en R (c)publique d (c)mocratique du Congo. PNLS. RDC 2019. Available at: https://www. prepwatch.org/wp-content/uploads/2022/03/DRC-National-PrEP-Guideliens-2019. pdf. Accessed April 24, 2023.
Ngongo NM, Darcis G, Nanituna HS, et al. Longitudinal analysis of sociodemographic, clinical and therapeutic factors of HIV-infected individuals in Kinshasa at antiretroviral therapy initiation during 2006-2017. PLoS One 2021; 16: e0259073.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a Public Health Approach. 2013 revision. Geneva, WHO 2013. Available at: http://apps. who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1. Accessed April 24, 2023.
Ngongo NM, Nani-Tuma HS, Mambimbi MM, et al. Progressive phasing out of baseline CD4 + cell count testing for people living with HIV in Kinshasa, Democratic Republic of the Congo. AIDS 2021; 35:841-3.
Lecher SL, Fonjungo P, Ellenberger D, et al. HIV viral load monitoring among patients receiving antiretroviral therapy "eight sub-Saharan Africa countries, 2013- 2018. MMWR Morb Mortal Wkly Rep 2021; 70:775-8.
Mayasi N, Situakibanza H, Mbula M, et al. Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the ‘treat-all (tm). Strategy. PLoS Global Public Health 2022; 2:e0000259.
UNAIDS. Ambitious treatment targets: writing the final chapter of the AIDS epidemic: writing the final chapter of the AIDS epidemic. Geneva, 2014. Available at: https://www.unaids.org/sites/default/files/media_asset/JC2670_UNAIDS_ Treatment_Targets_en.pdf. Accessed June 13, 2023.
Tymejczyk O, Brazier E, Yiannoutsos C, et al. HIV Treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: a metaregression analysis of programmatic data from 22 countries. PLoS Med 2018; 15:e1002534.
Hermans LE, Carmona S, Nijhuis M, et al. Virological suppression and clinical management in response to viremia in South African HIV treatment program: a multicenter cohort study. PLoS Med 2020; 17:e1003037.
Pillay T, Cornell M, Fox MP, et al. Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study. Antivir Ther 2020; 25:257-66.
Haas AD, Radin E, Hakim AJ, et al. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys. J Int AIDS Soc 2020; 23: e25631.
Fast-Track strategy to end the AIDS epidemic by 2030. Available at: https://www. unaids.org/en/resources/campaigns/World-AIDS-Day-Report-2014. Accessed April 24, 2023.
Kerschberger B, Schomaker M, Ciglenecki I, et al. Programmatic outcomes and impact of rapid public sector antiretroviral therapy expansion in adults prior to introduction of the WHO treat-all approach in rural Eswatini. Trop Med Int Health 2019; 24:701-14.
Hirasen K, Fox MP, Hendrickson CJ, Sineke T, Onoya D. HIV treatment outcomes among patients initiated on antiretroviral therapy pre and post-universal test and treat guidelines in South Africa. Ther Clin Risk Manag 2020; 16:169-80.
Wekesa P, McLigeyo A, Owuor K, Mwangi J, Nganga E, Masamaro K. Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in central Kenya. BMC Public Health 2020; 20:328.
Chammartin F, Z 1/4rcher K, Keiser O, et al. Outcomes of patients lost to follow-up in African antiretroviral therapy programs: individual patient data meta-analysis. Clin Infect Dis 2018; 67:1643-52.
Yotebieng M, Mpody C, Ravelomanana NL, et al. HIV viral suppression among pregnant and breastfeeding women in routine care in the Kinshasa province: a baseline evaluation of participants in CQI-PMTCT study. J Int AIDS Soc 2019; 22:e25376.
Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis 2018; 18:188-97.
Zhang T, Ding H, An M, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis 2020; 20:147.
Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis 2019; 69:2145-52.
Myer L, Redd AD, Mukonda E, et al. Antiretroviral adherence, elevated viral load, and drug resistance mutations in human immunodeficiency virus-infected women initiating treatment in pregnancy: a nested case-control study. Clin Infect Dis 2020; 70:501-8.
Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore) 2016; 95: e3361.
Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence 2019; 13:475-90.